← Company intelligence

Component supplier · early

Phantom Neuro

Corporate marketsensingconnectivityCurated record

Develops Phantom X, a minimally invasive implantable muscle-machine interface: sEMG electrode strips under the skin decode muscle signals with machine learning to give amputees and mobility-impaired users intuitive, natural control of robotic prosthetic limbs and exoskeletons. Johns Hopkins School of Medicine spinout (2020) now in preclinical testing heading to first-in-human trials; prosthetics leader Ottobock led its Series A and joined the board.

HeadquartersAustin, US
Founded2020
Corporate funding$28M
Team11-50
Deployments0
Open roles0
01

Company overview

Identity and operating footprint

Company typeComponent supplier
Market segmentCorporate
StageSeries A ($19M Apr 2025 led by Ottobock; $28M total)
FoundersConnor Glass (Founder & CEO)
Regions servedNorth America
Countries deployedNot listed
Service footprintNot listed
Last reviewed2026-07-05
CA

Funding history

Publicly announced rounds

Investors on recordOttobockBreakout VenturesDraper AssociatesLionBird VenturesTime BioVenturesActual VC
TL

Company timeline

Milestones and announcements

2025-04-15Raised oversubscribed $19M Series A led by Ottobock to fund preclinical testing, first-in-human trials, and regulatory submissions for Phantom XPR Newswire
SC

Source ledger

4 unique public sources